Tumor antigen

BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023

Retrieved on: 
Monday, October 23, 2023
Patient, NKI, Ovarian cancer, ESMO, American Society of Clinical Oncology, BioNTech, RNA, DCR, Neurotoxicity, Entrepreneurship, Society, CLDN6, Annual general meeting, Tumor antigen, ORR, Netherlands Cancer Institute, BNTX, Safety, ASCO, Vaccine, Pharmaceutical industry

The data show encouraging signs of clinical activity and an increased persistence of cancer-specific CAR-T cells when combined with CARVac.

Key Points: 
  • The data show encouraging signs of clinical activity and an increased persistence of cancer-specific CAR-T cells when combined with CARVac.
  • “Our goal is to unlock the potential of CAR-T for solid tumors and to help improve the outcomes for a broad range of hard-to-treat tumors,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech.
  • “BNT211 aims to address two of the key limitations of CAR-T cell approaches in solid tumors, namely the lack of suitable cancer-specific cell surface targets and the limited persistence of CAR-T cells.
  • Patients with germ cell tumors (n=16), ovarian cancer (n=17) and other solid tumor types (n=11) were treated.

AUA Releases Amendment to the Diagnosis and Treatment of Early-Stage Testicular Cancer Guideline

Retrieved on: 
Thursday, September 14, 2023
Cancer, IIB, Teratoma, Guideline, Retroperitoneal space, AUA, IIA, American Urological Association, Bleomycin, Toxicity, Cisplatin, Literature, SUFU, Testicular cancer, Etoposide, Estate (law), Patient, Surveillance, Diagnosis, Rush University Medical Center, Tumor antigen, ULR, Dentistry, Medical imaging, Medical device

BALTIMORE, Sept. 14, 2023 /PRNewswire/ -- Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the diagnosis and treatment of early-stage testicular cancer.

Key Points: 
  • BALTIMORE, Sept. 14, 2023 /PRNewswire/ -- Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the diagnosis and treatment of early-stage testicular cancer.
  • Testicular cancer is the most common solid malignancy in young males and is relatively rare, with outcomes defined by specific cancer and patient-related factors.
  • "Since the last testicular cancer guideline was released, the model for management has substantially changed, making an amendment like this critical to effectively treat and manage testicular cancer."
  • Diagnosis and treatment of early-stage testicular cancer: AUA Guideline amendment 2023.

SpIntellx and iCura Diagnostics Partner to Expand Access to Advanced Spatial Analytics and Explainable AI Products for Pathology and Oncology Research

Retrieved on: 
Thursday, August 18, 2022
Genomics, HIV disease progression rates, Laboratory, Biomarker, Drug discovery, CEO, Neoplasm, Pennsylvania Department of Corrections, CRO, Image analysis, Pathology, Phylogenetic inference using transcriptomic data, Environment, Software as a service, Proteomics, Patient, IHC, Therapy, Tumor antigen, Partnership, TME, Tumor microenvironment, Drug development, Doctor of Philosophy, Biology, Immunotherapy, Software, Solution, MD, CLIA, Pennsylvania Department of Health, Medical imaging, Online shopping

PITTSBURGH and MALVERN, Pa., Aug. 18, 2022 /PRNewswire-PRWeb/ -- SpIntellx, Inc., a leader in spatially intelligent biology and iCura Diagnostics, a leading contract research organization focused on capitalizing multiomic data to accelerate end-to-end clinical workflow solutions and biomarker discovery, have announced a partnership to transform precision oncology through unlocking the power of genomic, proteomics, and transcriptomic data using advanced spatial analytics.

Key Points: 
  • This new partnership combines SpIntellx's software as a service (SaaS) based solutions for precision pathology applications harnessing unbiased spatial analytics and explainable AI with iCura Diagnostics' expertise as a technical CRO propelling the pace of immunotherapy and targeted therapy development.
  • Through this strategic alliance, iCura Diagnostics and SpIntellx will deliver advanced spatial analytics and explainable AI-powered decisions at scale across the drug development continuum driving integration of multimodal data, optimizing clinical workflow, accelerating biomarker discovery, and empowering personalized care.
  • Their novel approaches include unlocking key spatial interactions through the discovery of microdomains in the TME which contribute to disease progression and proliferation.
  • Our combined expertise in multiplexing (or multiplex spatial imaging), explainable AI and unbiased spatial analytics will radically transform spatial biology and generate hitherto unprecedented spatial insights to radically improve our approach to immunotherapy in the future."

Creatv Bio’s LifeTracDx® Liquid Biopsy Predicts Response to New Line of Therapy for Metastatic Breast Cancer within 30 Days

Retrieved on: 
Sunday, June 5, 2022
Oncology, Health, Medical Devices, Research, Science, Pharmaceutical, Biotechnology, Prognosis, Immunotherapy, Society, Biotechnology, MBC, Cancer, Minimal residual disease, B cell, Breast cancer, Blood, Tumor antigen, Chinese, Transmembrane activator and CAML interactor, Bio, American Society of Clinical Oncology, Patient, Publication, Division, Downtown San Jose, Technology, DNA, TSX, NASDAQ, BCT, Medical imaging

We are hopeful that the technology will allow us to better identify breast cancer patients most likely to benefit from novel therapies.

Key Points: 
  • We are hopeful that the technology will allow us to better identify breast cancer patients most likely to benefit from novel therapies.
  • Creatvs LifeTracDx liquid biopsy is a commercialized Research Use Only test for the analysis of Circulating Tumor Cells (CTCs) and Cancer Associated Macrophage-like Cells (CAMLs).
  • LifeTracDx tests are applicable for cancer screening, companion diagnostics, prediction of treatment response (including immunotherapy), prognosis, detection of residual disease at end of therapy, and early detection of cancer recurrence.
  • Creatv Bio, Division of Creatv MicroTech, is a privately-held cancer diagnostic company which pioneered LifeTracDx liquid biopsy and CellSieveTM microfilters for cancer screening and diagnostics.

Replimune to Present at Two Upcoming Investor Conferences

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Clinical medicine, Branches of biology, Oncology, Immune system, Cancer immunotherapy, Vaccines, Cancer, Antigen, Tumor antigen, Treatment of cancer, Combinatorial ablation and immunotherapy

Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released.

Key Points: 
  • Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released.
  • Replimunes Immulytic platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes.
  • The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers.
  • Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications.For more information, please visit www.replimune.com .

ImmunityBio’s Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. Patent

Retrieved on: 
Tuesday, July 27, 2021
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Clinical medicine, Medicine, Vaccination, Virotherapy, Oncology, Cancer vaccine, Tumor antigen, Immunotherapy, Adenoviridae, Vaccine, Cancer

ImmunityBio, Inc., a publicly traded immunotherapy company, announced today that it has been granted a patent by the U.S. Patent and Trademark Office for its proprietary NANT Cancer Vaccine (U.S. Patent 11,071,774).

Key Points: 
  • ImmunityBio, Inc., a publicly traded immunotherapy company, announced today that it has been granted a patent by the U.S. Patent and Trademark Office for its proprietary NANT Cancer Vaccine (U.S. Patent 11,071,774).
  • The tumor antigens are then targeted by antigen-specific T-cells activated via ImmunityBios adenoviral- and yeast-based vaccine vectors.
  • To study the safety and early efficacy signals across multiple tumor types, the company has launched a series of Quantitative Lifelong Trials ( QUILT ).
  • To date, the NANT Cancer Vaccine has been studied in more than 100 patients across multiple tumor types, including pancreatic , breast , colorectal, and head and neck cancers.

INVECTYS INC. TO PARTICIPATE IN THE 2021 ROTH VIRTUAL HEALTHCARE PRIVATE COMPANY FORUM ON JUNE 28TH, 2021

Retrieved on: 
Friday, June 25, 2021
Clinical medicine, Medicine, Branches of biology, Oncology, Cancer immunotherapy, Immunotherapy, Virotherapy, Telomerase, Tumor antigen

Dr. Tyle will speak on the panel titled Novel Approaches to Tumor Eradication at 9:00a.m.

Key Points: 
  • Dr. Tyle will speak on the panel titled Novel Approaches to Tumor Eradication at 9:00a.m.
  • Invectys, Inc focuses on a multi-modality approach to targeting HLA-G on tumor cells and also an approach with universal tumor antigen telomerase.
  • Invectys, Inc. is a clinical stage immuno-oncology company spun-out of the world renown Pasteur Institute, Paris.
  • Since 2010, Invectys has raised over $58 million in private funds to develop two innovative platforms of immunotherapy products which target universal tumor antigens.

ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021

Retrieved on: 
Thursday, May 20, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Medical specialties, Clinical medicine, Branches of biology, Immunology, Oncology, Immune system, T cells, Tumor antigen, Immunotherapy

These resistant clones accomplish this \xe2\x80\x9ccloaking ability\xe2\x80\x9d by preventing the presentation of the tumor antigens on MHC-I receptors, thus \xe2\x80\x9chiding\xe2\x80\x9d from killer T cells.

Key Points: 
  • These resistant clones accomplish this \xe2\x80\x9ccloaking ability\xe2\x80\x9d by preventing the presentation of the tumor antigens on MHC-I receptors, thus \xe2\x80\x9chiding\xe2\x80\x9d from killer T cells.
  • For these patients, maximum activation of T cells with immunotherapy is unlikely to lead to durable tumor control or a cure.
  • For more information, please visit: www.immunitybio.com\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.

MANA Therapeutics Appoints Arthur Hurwitz as Chief Scientific Officer

Retrieved on: 
Monday, May 10, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, Biology, Life sciences, Stem cells, Oncology, Biotechnology, Cell biology, Cell therapy, Agenus, Tumor antigen, EDIFY™, MANA Therapeutics, EDIFY™, MANA THERAPEUTICS

b'MANA Therapeutics , a clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, today announced the appointment of Arthur (Andy) Hurwitz, Ph.D., to the newly created position of Chief Scientific Officer.

Key Points: 
  • b'MANA Therapeutics , a clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, today announced the appointment of Arthur (Andy) Hurwitz, Ph.D., to the newly created position of Chief Scientific Officer.
  • Dr. Hurwitz previously served as Senior Vice President and Head of Research at MANA.
  • In addition, Michael Kuo MT (ASCP) has been appointed as Senior Vice President of Technical Operations.\nThis press release features multimedia.
  • Dr. Hurwitz was also Senior Director of TCR Biology at Agenus where he held responsibilities for both vaccine and cell therapy activities.

Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021

Retrieved on: 
Thursday, April 29, 2021
Clinical medicine, Medicine, Medical specialties, Oncology, Virotherapy, Cancer immunotherapy, Tumor antigen, Immunotherapy, Pelareorep, Adoptive cell transfer

Individuals can participate in the conference call by dialing 877-407-8913 (domestic) or 201-689-8201 (international) and referring to the "Marker Therapeutics First Quarter 2021 Earnings Call.

Key Points: 
  • Individuals can participate in the conference call by dialing 877-407-8913 (domestic) or 201-689-8201 (international) and referring to the "Marker Therapeutics First Quarter 2021 Earnings Call.
  • "\nThe archived webcast will be available for replay on the Marker website following the event.\nMarker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
  • Marker\'s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e.
  • This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient\'s immune system to produce broad spectrum anti-tumor activity.